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Abstract We have previously described a novel cancer che-
motherapeutic approach based on the induction of apoptosis
in targeted cells by homing pro-apoptotic peptides. In order
to improve this approach we developed a computational method
(approach for detecting potential apoptotic peptides, APAP)
to detect short PAPs, based on the prediction of the helical
content of peptides, the hydrophobic moment, and the iso-
electric point. PAPs are toxic against bacteria and mito-
chondria, but not against mammalian cells when applied
extracellularly. Among other peptides, substance P was identi-
fied as a PAP and subsequently demonstrated to be a pro-
apoptotic peptide experimentally. APAP thus provides a method
to detect and ultimately improve pro-apoptotic peptides for
chemotherapy. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
We have previously described the ¢nding that an antibacte-
rial peptide, when targeted intracellularly to the angiogenic
vasculature (i.e. to the endothelial cells) supplying tumors,
can induce apoptosis by swelling their mitochondria [1], lead-
ing to the loss of tumor blood supply and consequent tumor
regression. We named these chemotherapeutic peptides hom-
ing pro-apoptotic peptides. We designed the pro-apoptotic
part of the peptides to induce endothelial cell apoptosis
through mitochondrial swelling. The peptides are positively
charged and the mitochondria, like bacteria, have negatively
charged membranes, thus the peptides are attracted to and
disrupt the mitochondrial membrane [2,3]. The initial results
were obtained with a 21-residue peptide, of which the car-
boxy-terminal 14 amino acids represented the pro-apoptotic
peptide, with the amino-terminal seven amino acids compris-
ing the targeting peptide and a glycinylglycine bridge. The
therapeutic index (TI) of the initial pro-apoptotic peptides is
approximately 10. In order to increase the TI and minimize
the length of these peptides, we designed a computational
approach to detect short, linear and speci¢c pro-apoptotic
peptides.
Apoptosis in mammals and other eukaryotic organisms is a
characteristic process of cell death, which can, among its other
e¡ects, limit the spread of viruses and other intracellular or-
ganisms [4]. For example, the di¡erence in viral titer during
baculoviral infection with and without apoptosis inhibition is
200^15 000-fold [4]. Thus apoptosis is a mechanism of defense
against pathogenic infections.
Apoptosis proceeds by the activation of a group of cysteine
proteases called caspases [5]. One of these, caspase-9, is acti-
vated when cytochrome c is released from mitochondria,
which may occur with the disruption of the mitochondrial
outer membrane [6]. This cytochrome c release in apoptotic
cells may be induced by pro-apoptotic members of the Bcl-2
family, such as Bax and Bid, although the mechanism by
which this is achieved is incompletely understood [7]. None-
theless, the similarities between bacterial and mitochondrial
membranes (and membrane potentials) suggested the possibil-
ity that there may be similarities between the e¡ect of the
antibacterial/pro-apoptotic peptides and pro-apoptotic Bcl-2
family members.
Antibacterial peptides in multicellular organisms are
thought to serve as a defense against microbial pathogens.
Originally found in invertebrates, antibacterial peptides have
now been described in humans and many other organisms [2].
Among these peptides, the most well characterized are the
short linear peptides (less than 40 amino acids in length)
that do not contain cysteine residues. A characteristic shared
by virtually all of these peptides is the presence of an amphi-
pathic K-helical structure, which stabilizes in environments of
hydrophobic nature [8] (although this helical structure has
been shown not to be necessary for membrane lysis produced
by a truncated form of pardaxin, an antibacterial peptide
from the sole Pardachirus marmoratus [9]). Another character-
istic shared by some of these peptides is selectivity, in that
membranes from bacteria are targeted by these peptides
more e⁄ciently than mammalian plasma membranes. This
selectivity is based on the complementary charge between
the peptides, which are characteristically positively charged,
and the negatively charged membranes of bacteria [2,3].
Structurally, these peptides typically adopt an unfolded
conformation in aqueous solution. On contact with a mem-
brane with a complementary charge, these peptides anchor to
the membrane and assume an K-helical conformation. In that
conformation, these peptides would either lie over the mem-
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brane surface in a carpet-like arrangement (in which the pep-
tide backbone lies parallel to the membrane), or penetrate it
according to the barrel^stave mechanism (in which the peptide
backbone lies perpendicular to the membrane) [2]. In either
case, the integrity of the membrane would be disturbed, even-
tually leading to membrane lysis.
In order to optimize the homing pro-apoptotic peptide ap-
proach to cancer chemotherapy by maximizing the TI (see
Section 2), we have developed a theoretical approach intended
to model the properties of the antibacterial peptides that
present selectivity for bacteria (and thus have very low toxic
e¡ects on mammalian cells when applied extracellularly). It is
our goal in this work to develop a sequence-pattern recogni-
tion approach to detect peptides that will be toxic towards
mitochondria but not to mammalian cells when applied ex-
tracellularly. We refer to the peptides identi¢ed by this ap-
proach as potential apoptotic peptides (PAPs), since they may
induce apoptosis by swelling mitochondria when targeted in-
tracellularly, as previously described [1]. We refer to the ap-
proach as APAP, as an abbreviation for approach for detect-
ing PAPs. Using APAP, we searched the SwissProt database
for PAPs and among other peptides we found that substance
P (SP), an extensively studied neuropeptide present in mam-
mals, birds and ¢sh, has all the sequence characteristics of the
PAPs. Furthermore, we found that SP is capable of swelling
mitochondria and inducing the cleavage of caspase-3 zymo-
gen, a known substrate of the active form of caspase-9 in
vitro. As expected, SP demonstrated very low toxicity for
eukaryotic cells when applied extracellularly, in addition to
displaying toxicity towards bacterial cells. These results sup-
port our sequence-pattern recognition approach to identifying
new PAPs, and suggest a new role for SP in the brain.
2. Materials and methods
2.1. Sequence-pattern recognition approach
We noticed that the known antibiotic peptides ¢t a pattern, which
includes a low likelihood of helicity in aqueous solution, a high like-
lihood of helicity in the presence of negatively charged membranes,
and a high isoelectric point (IP). We therefore calculated the helical
probability of monomeric peptides in aqueous solution (AGADIR
score), the IP and the hydrophobic moment to account for the char-
acteristics of antibacterial peptides with low toxic activity against
mammalian cells. We hypothesized that these characteristics are im-
portant in determining the selectivity observed in these peptides to-
wards bacterial membranes and bacterial-like membranes (i.e. mito-
chondrial membranes).
A subset of 30 antibacterial peptides previously reported in the
literature was used for calculations of AGADIR scores (A) [10], IP,
and average helical hydrophobic moments (M) [11], (Tables 2A and
2B). The peptide sequences of this subset are shown in Table 1.
The TI of a peptide is here de¢ned as the ratio between the inhib-
itory concentration observed with mammalian cells and the inhibitory
concentration observed with bacterial cells (Tables 2A and 2B). The
higher the value of this ratio is, the more speci¢c the peptide is for
prokaryotic (negatively charged) membranes.
PAPs were searched for in the SwissProt database, release 38 [12],
which contains a total of 80 000 protein sequences. First, all of the
peptide sequences of 40 or fewer amino acids in length were extracted
from this database. Then all of these sequences (2473 database entries)
were used to calculate their corresponding M, IP and AGADIR
scores. Protein fragments, as opposed to peptides, were not considered
in this study.
2.2. Computational resources
The PEPPLOT and ISOELECTRIC programs from the GCG
package (Wisconsin package version 10, USA) were used to calculate
M and IP, respectively. We averaged the non-zero K-values calculated
by the PEPPLOT program (see Section 2) for windows of eight res-
idues. To calculate the AGADIR score, we used the AGADIR pro-
gram, which was kindly provided by Dr. Luis Serrano at EMBL. The
hydrophobicity of peptide sequences was obtained by calculating the
average hydrophobicity of the sequence using the consensus scale
reported by Eisenberg [11]. All these programs were run on a SGI
Origin 2000 server.
2.3. Caspase-3 activation in a cell-free apoptosis system induced by SP
2.3.1. Preparation of cytoplasmic extracts. Cytoplasmic extracts
were prepared as described before [18]. Brie£y, non-apoptotic neuro-
nal cells were sonicated and centrifuged at 16 000Ug. This extract was
made free of nuclei, mitochondria and did not self-prime.
2.3.2. Preparation of mitochondria. Rat and mouse liver mito-
chondria were prepared as described by Hovius et al., [13], with mod-
i¢cations as described previously [14]. Cultured cell mitochondria were
prepared as described previously [15].
2.4. Protein electrophoresis and Western blots
Electrophoresis of proteins was carried out using either 8 or 12%
SDS^polyacrylamide gels. Equal amounts of total protein were loaded
per lane, and the proteins were separated at 4‡C at 50 V through the
stacking gel, and 90 V through the separating gel.
Western blot transfer of the proteins separated by electrophoresis
was carried out at 4‡C using PVDF membranes (0.2 mm) (Bio-Rad),
at either 200 mA for 2 h. Blots were then blocked for 1 h in TBST (10
mM Tris^HCl, pH 7.5, 150 mM NaCl, 0.1% Tween) containing 5%
non-fat dried milk. Finally, the membranes were probed with an ap-
propriate dilution (1:500 to 1:2000) of primary antibody in TBST
containing 5% non-fat dried milk for 1^4 h, depending upon the anti-
body.
Anti-caspase-3 antibodies from mouse, rabbit and goat were pur-
chased from Transduction Laboratories, Inc., Upstate Biotechnology,
Inc. and Santa Cruz Biotechnology, Inc., respectively.
The blots were washed three times for 1 h with TBST, followed by
incubation in a peroxidase-coupled secondary antibody for 1 h in
TBST containing 5% non-fat dried milk. The mouse, human, and
rabbit peroxidase-coupled secondary antibodies were from Amer-
sham. Enhanced chemiluminescence detection of the proteins was
carried out using Hyper¢lm ECL (Amersham), and with Pierce Super-
Signal Substrate Western Blotting reagents, or Amersham ECL re-
agents.
2.5. Mitochondrial swelling assays
Rat liver mitochondria were prepared as described above. The pep-
tide concentrations used to swell mitochondria were 50 WM L-SP, 10
WM D-(LSLARLATARLAI) (negative control), or 200 WM Ca2 (pos-
itive control). The swelling was quanti¢ed by measuring the optical
absorbance at 540 nm.
2.6. Activity of SP on ¢broblasts
104 human embryonic kidney 293 cells per well were seeded into a
96-well plate. After 20 h, di¡erent aqueous dilutions (Fig. 2B) of SP
(Sigma, USA), C31 and a peptide used as a control were added to the
culture and the cell death was quanti¢ed by trypan blue exclusion 48 h
later.
2.7. Toxicity of SP for bacterial cells
DH5K Escherichia coli cells were grown overnight as a pre-inocu-
lum for the bacterial culture used in this assay. When the cells were at
the end of their log phase (optical density at 600 nm of 0.8^1.0), 1 Wl
was used to inoculate 5 ml. Such dilution produced initial concentra-
tions of bacteria capable of forming 105^106 colonies per ml in LB
plates at 37‡C, that is 105^106 colony forming units. All the bacterial
cultures used in these experiments were grown in LB at 37‡C. The
concentration of SP required to inhibit the cell growth by 60% was
determined by following bacterial growth in LB liquid in the presence
of varying concentration of the peptide: 0, 1, 10, 20, 50, 125, and 250
WM. Sterilized 96-well plates of polystyrene with £at bottom and low
evaporation lid (Costar, USA) were used, in a ¢nal volume of 100 Wl :
50 Wl of LB containing 105^106 colony forming units, and 50 Wl of LB
with a 2-fold dilution of the peptide. A 10 mM stock solution of the
peptide was prepared with 5 mg of SP in 371 Wl of water. Inhibition of
growth was detected by measuring optical density at 600 nm with a
microplate spectrophotometer SPECTRAmax (Molecular Devices,
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USA) at varying times: 0, 3, 5, 6, 7 and 8 h. Each IC60 was deter-
mined from at least two independent experiments performed in trip-
licate. Additionally, the colonies formed from each experiment were
counted in LB plates at 0 and 8 h of growth.
3. Results
The antibacterial peptides analyzed and biophysical proper-
ties previously determined are presented in Tables 1 and 2A,
respectively.
In order to reproduce these biophysical properties, we cal-
culated three scores from the sequences of these peptides.
Table 2A shows a subset of selected antibacterial peptide se-
quences (see Section 2) and the corresponding experimental
values for helix formation in water and in hydrophobic envi-
ronments, antibacterial activity and cytotoxic activities against
mammalian cells. Table 2B shows the corresponding calcu-
lated values for M, IP, A and the TI. We observed that the
antibacterial peptides presented in Table 1 are more potent
against G(3) (MIC = 17.3 Wg/ml on average) bacteria than to
G(+) (MIC = 44.3 Wg/ml), and we used the G(3) values as a
reference for the TI.
Peptide sequences with values ranging from 0.46M6 0.6,
A6 10.0 and 10.86 IP6 11.7, were found to have the highest
TI (highest speci¢city for bacteria) (Table 2B). These param-
eters were therefore hypothesized to be the signature of the
PAPs. Searching for PAPs in the SwissProt database led us to
identify 14 PAPs (Table 3). Two of these peptides have pre-
viously been characterized with respect to their toxicity
against bacteria and mammalian cells, and in both cases a
greater toxicity towards bacterial cells was observed (Table 3).
3.1. Swelling of mitochondria and activation of caspase-3 by SP
One of the PAPs identi¢ed, SP, was tested for its ability
to swell mitochondria and induce caspase-3 activation in a
cell-free system. This system was developed previously in
our group to simulate neuronal apoptosis (see Section 2
and [14]). We observed that SP induces the swelling of mito-
chondria at 50 WM in our system (data not shown). At such
concentration, SP was capable of releasing cytochrome c
from mitochondria and activating caspase-3 (Fig. 1). In con-
trast, a peptide chosen as negative control (see Section 2)
which did not present the properties of PAPs (data not
shown) did not display any observable e¡ect on mitochondria
(Fig. 1).
3.2. TI of SP
The toxicity of SP against bacteria was tested and com-
pared to the e¡ect of SP on ¢broblasts when applied extra-
cellularly. SP was able to reduce the growth of E. coli cells
with an IC60 of 10 WM (Fig. 2B). By comparison, the negative
control peptide did not have any toxicity against bacteria. In
contrast, Fig. 2A shows that SP did not a¡ect the growth of
¢broblasts when applied extracellularly even at a concentra-
tion of 1 mM. These results indicate that SP has a TIs 100.
Additionally, a peptide from the protein APP (the last 31
amino acids in APP, referred as C31) known to induce apo-
ptosis when expressed intracellularly [16] was tested for its
toxicity against bacteria and mammalian cells. This peptide
did not present the properties (IP, M, A scores) of PAPs
(data not shown). C31 did not present any observable toxicity
against bacterial or mammalian cells when applied extracel-
lularly (Fig. 2A,B).
Table 1
Peptide sequences of a subset of antibacterial peptides
Peptide name Peptide sequence
(KIAKKIA)2NH2 KIAKKIAKIAKKIA-NH2
(KIAKKIA)3NH2 KIAKKIAKIAKKIAKIAKKIA-NH2
(KIAKLAK)2NH2 KIAKLAKKIAKLAK-NH2
(KIAKLAK)3NH2 KIAKLAKKIAKLAKKIAKLAK-NH2
(KALKALK)3NH2 KALKALKKALKALKKALKALK-NH2
(KLGKKLG)3NH2 KLGKKLGKLGKKLGKLGKKLG-NH2
CecropinA KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ-NH2
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS-NH2
CA(1^13)M(1^13)NH2 KWKLFKKIEKVGQGIGAVLKVLTTGL-NH2
CA(1^8)M(1^18)NH2 KWKLFKKIGIGAVLKVLTTGLPALIS-NH2
Kla1 KLALKLALKAWKAALKLA-NH2
Kla2 KLALKAALKAWKAAAKLA-NH2
Kla3 KLALKAAAKAWKAAAKAA-NH2
Kla7 KAIAKSILKWIKSIAKAI-NH2
Kla8 KALAALLKKWAKLLAALK-NH2
Kla9 KLLAKAALKWLLKALKAA-NH2
Kla10 KALKKLLAKWLAAAKALL-NH2
Kla11 KITLKLAIKAWKLALKAA-NH2
Kla12 KALAKALAKLWKALAKAA-NH2
m2a GIGKFLHSAKKFGKAFVGEIMNS-NH2
W16-m2a GIGKFLHSAKKFGKAWVGEIMNS-NH2
L2R11A20-m2a GLGKFLHSAKRFGKAFVGEAMNS-NH2
I6L15-m2a GIGKFIHSAKKFGKLFVGEIMNS-NH2
I6A8L15I17-m2a GIGKFIHAAKKFGKLFIGEIMNS-NH2
I6R11R14W16-m2a GIGKFIHSAKRFGRAWVGEIMNS-NH2
I6V9W12T15I17-m2a GIGKFIHSVKKWGKTFIGEIMNS-NH2
100-m2a GIAKFGKAAAHFGKKWVGELMNS-NH2
140-m2a GIGKFLHTLKTFGKKWVGEIMNS-NH2
160-m2a GIGHFLHKVKSFGKSWIGEIMNS-NH2
The amino acids in the peptide sequence are represented in a one-letter code.
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4. Discussion
In order to optimize our homing pro-apoptotic approach to
target and kill angiogenic endothelial cells supplying cancer
cells, we have developed APAP, an approach to detect PAPs.
APAP was originally developed to overcome the problems of
toxicity and synthesis associated with our chemotherapeutic
approach [1]. Positively charged PAPs, which are non-toxic
outside the cell, are targeted to tumor vasculature by a fusion
with a peptide that recognizes a receptor on the cell surface
[17,18] and consequently internalized where they disrupt the
negatively charged mitochondria, thereby exerting their pro-
apoptotic e¡ect.
We calculated the amphipathicity, IP and AGADIR scores
for a subset of 30 di¡erent antibacterial peptides. The values
grouping those peptides with the highest TI were considered
the signature of PAPs. We searched for PAPs that resemble
antibacterial ones, based on the posited relationship between
mitochondrial-dependent apoptosis mechanisms and antibac-
terial activity. APAP provided us with a tool to identify PAPs
independently of any sequence similarity with other known
antibacterial or pro-apoptotic peptides. Additionally, APAP
allowed us to search sequence databases systematically.
We calculated the amphipathicity and IP because amphi-
pathic peptides are known to be membrane-associated [11],
and the selectivity for recognizing bacterial-like membranes
depends on the composition of the membranes [2,3]. Addi-
tionally, it has been previously recognized that hydrophobic
peptides display both antibacterial activity and toxicity
against mammalian cells [19] (i.e. non-selective toxicity),
thus PAPs would be expected not to be simply highly hydro-
phobic peptides. We observed that in our group of peptides
(Table 1), all of the peptides but one were hydrophilic, con-
stituting an appropriate group of peptides from which to se-
lect PAPs. It has been shown previously that antibacterial
peptides with lower hydrophobicity display higher speci¢city
towards Gram-negative bacteria [20]. In agreement with this
notion, all the peptides analyzed in our study presented higher
speci¢city towards G(3) bacteria as expressed by the TI val-
ues (Tables 2A and 2B).
Alternatively, the propensity to form soluble structures in
water (expressed by the propensity to form secondary struc-
Table 2A
Observed characteristics of a subset of antibacterial peptides
Peptide CD Water Observed lipid Antibacterial Gram(3) Activity Gram(+) Cytotoxicity Reference
(KLAKKLA)2NH2 6 5 24 6 6 s 272 [8]
(KLAKKLA)3NH2 6 5 79 4 4 s 11 [8]
(KLAKLAK)2NH2 6 5 37 6 6 s 517 [8]
(KLAKLAK)3NH2 6 5 79 4 4 s 9 [8]
(KALKALK)3NH2 6 5 67 4 8 11 [8]
(KLGKKLG)3NH2 6 5 33 4 4 s 393 [8]
Cecropin A 0 75 0.2 s 300 s 200 [24]
Melittin 0 75 0.8 s 0.2 s 400 [24]
Magainin 2 0 44 4 300 300 [24]
CA(1^13)M(1^13)NH2 0 55 0.5 2 s 200 [24]
CA(1^8)M(1^18)NH2 0 63 0.3 1 s 600 [24]
Kla1 ND 73 5.2 2.6 11 [25]
Kla2 ND 68 11 45 107 [25]
Kla3 ND 59 91 s 91 s 200 [25]
Kla7 ND 70 5.6 1.4 1.8 [25]
Kla8 ND 62 5.8 3 2.5 [25]
Kla9 ND 55 6.2 1.6 1.7 [25]
Kla10 ND 62 6.1 1.5 2 [25]
Kla11 ND 69 5.3 5.3 10 [25]
Kla12 ND 67 6 1.5 10 [25]
m2a ND 57 40 s 80 428 [25]
w16-m2a ND 57 40 s 80 509 [25]
l2r11a20m2a ND 45 75 s 75 s 100 [25]
i6l15-m2a ND 57 38 38 260 [25]
i6a8l15i17m2a ND 61 2.4 9.6 32 [25]
i6r11r14w16m2a ND 52 37.5 s 75 303 [25]
i6v9w12t15i17-m2a ND 64 2.3 18 56 [25]
100-m2a ND 48 75 s 75 700 [25]
140-m2a ND 75 13 13 35 [25]
160-m2a ND 54 19 76 82 [25]
Peptide: see Table 1 for the amino acid composition for each peptide described in this table. CD Observed in water or lipid: percent of K-heli-
cal secondary structure determined by circular dichroism. Antibacterial activity G(+) or G(3) : the minimal inhibitory concentration (Wg/ml) for
each peptide against Gram(+) and Gram(3) bacterial cells. Cytotoxicity: the concentration (Wg/ml) required for inhibiting the growth of mam-
malian cells, usually red blood cells or ¢broblasts.
Fig. 1. Pro-apoptotic activity of SP. The release of cytochrome c
from mitochondria and the processing of caspase-3 into the active
form are shown for SP and controls (sonication, the detergent Tri-
ton X-100 and a non-toxic peptide DLSLARLATARLAI).
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tures in water, AGADIR score) was used in our approach.
Since hydrophobicity and the propensity to form soluble
structures in water are inversely related, it is expected that
hydrophobic sequences will display a low AGADIR score.
The inverse is not necessarily true, though; that is, peptide
sequences with low AGADIR scores are not necessarily hy-
drophobic. Interestingly, PAPs tend to be hydrophilic with
low AGADIR scores (Tables 2B and 3).
The peptides used to de¢ne the parameters of the PAPs
(Table 1) are mostly synthetic peptides, with the exception
of three natural peptides (magainin, cecropin A and melittin).
None of these three natural peptides in Table 1 were detected
in our analysis because they were deposited in the SwissProt
database in their mature form. In this form, they were longer
than the cut-o¡ value used to de¢ne the peptide database
analyzed in this study (see Section 2 for a description of the
peptide database used in this study). Alternatively, two cecro-
pins (cec4_bommo, cecb_antpe) and two other natural anti-
bacterial peptides (crbl_vescr, dms3_physa) were found in our
search. In agreement with our predictions, these antibacterial
peptides have been reported to have TIs similar to PAPs (Ta-
ble 3). As further evidence of the validity of our approach, we
tested two peptides, C31 and a control, that did not match the
IP, M and A scores of PAPs (Fig. 2). The C31 peptide has
Table 2B
Calculated characteristics of a subset of antibacterial peptides
Peptide A M IP GHf TI
(KLAKKLA)2NH2 4.5 0.48 11.5 30.249 45.3
(KLAKKLA)3NH2 16.2 0.48 11.7 30.249 2.8
(KLAKLAK)2NH2 5.1 0.48 11.5 30.249 86.2
(KLAKLAK)3NH2 17.2 0.48 11.7 30.249 2.3
(KALKALK)3NH2 16.6 0.48 11.7 30.249 2.8
(KLGKKLG)3NH2 1.1 0.49 11.7 30.274 98.3
Cecropin A 1.2 0.44 11.2 30.123 1000.0
Melittin 3.1 0.46 12.6 30.83 500.0
Magainin 2 0.8 0.56 10.8 30.036 75.0
CA(1^13)M(1^13)NH2 1.1 0.53 11.1 30.46 400
CA(1^8)M(1^18)NH2 1.3 0.43 11.4 0.065 2000
Kla1 13.4 0.16 11.4 30.025 2.1
Kla2 10.6 0.30 11.4 30.056 9.7
Kla3 7.2 0.17 11.4 30.087 2.2
Kla7 2.4 0.53 11.4 30.026 0.3
Kla8 49 0.51 11.4 30.025 0.4
Kla9 18 0.38 11.4 30.025 0.3
Kla10 23.5 0.45 11.4 30.025 0.3
Kla11 14.8 0.16 11.4 30.027 1.9
Kla12 19.5 0.49 11.4 30.056 1.7
m2a 0.8 0.56 10.8 30.036 10.7
w16-m2a 0.9 0.49 10.8 30.046 12.7
12r11a20-m2a 0.9 0.51 11.1 30.094 13.3
i6l15-m2a 0.6 0.54 10.8 30.095 6.8
i6a8l15i17-m2a 1.1 0.55 10.8 0.016 13.3
i6r11r14w16-m2a 0.8 0.48 11.7 30.095 8.1
i6v9w12t15i17-m2a 0.7 0.56 10.8 30.035 24.3
100-m2a 1.1 0.46 10.8 30.045 9.3
140-m2a 0.9 0.57 10.8 30.049 2.7
160-m2a 0.7 0.57 10.5 30.017 4.3
Peptide: see Table 1 for the amino acid composition for each peptide described in this table. A : AGADIR score. M : average helical hydropho-
bic moment. IP: estimated isoelectric point. GHf : averaged hydrophobicity. TI: calculated therapeutic index.
Table 3
PAPs in the SwissProt database
SwissProt name A M IP GHf Length Antibacterial activity Gram(3) Cytotoxicity Reference
Bol1_megpe 7.9 0.52 11.1 0.058 17
Cec4_bommo 0.5 0.44 11.3 30.097 35
Cecb_antpe 0.5 0.43 11.5 30.132 35
Crbl_vescr 0.7 0.50 11.6 0.144 13 15 s 120 [24]
Dms3_physa 1.7 0.44 11.1 30.024 30 2.5 80 [26]
Grar_ranru 0.04 0.53 11.6 30.084 12
Ranr_ranru 1.3 0.44 11.6 30.239 17
Npf_arttr 4.3 0.45 10.9 30.297 36
sp5m_bacsu 2.5 0.55 11.4 30.095 26
Stp_bpt4 1.7 0.43 11.1 30.278 26
Tkna_gadmo 0.03 0.48 11.6 30.190 11
Tkna_horse 0.03 0.51 11.6 30.201 11
Tkna_oncmy 0.01 0.49 11.6 30.175 11
Tkna_scyca 0.03 0.49 11.6 30.124 11
SwissProt name: the accession name in the SwissProt database for that particular peptide. A : AGADIR score. M : average helical hydrophobic
moment. IP: calculated isoelectric point. GHf : averaged hydrophobicity. Cytotoxicity: the concentration (Wg/ml) required for inhibiting the
growth of mammalian cells, usually red blood cells or ¢broblasts.
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been shown to induce apoptosis by an unknown mechanism
[16], so we considered it an interesting target for our study
since we might provide some hints on the mechanism of ac-
tion of C31 in addition to testing our approach. We found
that none of these peptides is toxic to bacterial or mammalian
cells when applied extracellularly thus con¢rming our predic-
tions. Based on these results we propose that C31 may induce
apoptosis by a di¡erent mechanism than PAPs.
In total, 14 sequences were identi¢ed as PAPs in the Swiss-
Prot database (see Section 2). These 14 peptides can be placed
into four di¡erent groups based on their known function; i.e.
antibacterial peptides, neuropeptides, mast cell degranulating
peptides and protein^protein interacting peptides. Two out of
these four groups, antibacterial peptides and neuropeptides,
represent more than 80% of the total (Table 3). Neuropeptides
appear to be over-represented since there were only 48 neuro-
peptides in the original pool of 2473 peptides in the SwissProt
database.
The special need for antibacterial peptides in the mamma-
lian brain has been pointed out previously [21], since these
may represent a more immediate line of control for bacterial
infection than the immune system (which has a restricted ac-
cess to the brain). Considering the properties of PAPs, our
¢ndings suggest that some previously identi¢ed neuropeptides
may have antibacterial activity.
Among the neuropeptides identi¢ed as PAPs (Table 3), four
were homologs of SP: tkna_gadmo, tkna_horse, tkna_oncmy,
and tkna_scyca. SP belongs to the tachykinin family. Tachy-
kinins are synthesized as larger protein precursors (usually
more than 40 amino acids in length) that are enzymatically
converted to their mature forms [22]. In our original search,
we were able to detect only those recorded in the SwissProt
database in the active form. Analyzing all of the tachykinins
deposited in the database (precursors and active forms), we
found that 10 out of 61 were predicted to be PAPs (data not
shown). Notably, these 10 were SP peptides from di¡erent
species.
SP is known to form an K-helical structure in hydrophobic
environments but not in aqueous solution [23], while it has a
positive charge distribution over its sequence, supporting the
¢nding that SP is a PAP. Therefore, the neuropeptide SP was
tested for its preference for mitochondria-like membranes.
The results presented in this work support our predictions
that SP is a PAP. However, we did not observe a complete
inhibition of E. coli growth, probably because of its well
known short half-life in solution (minutes), while our experi-
ments lasted for 8 h. Another possibility is that SP only dis-
plays a bacteriostatic activity, since the toxicity displayed by
SP on bacterial cells was not markedly a¡ected by the con-
centration of SP, as in the case of antibacterial peptides.
In developing APAP we focused on the characteristics that
de¢ne selectivity rather than e⁄ciency to kill bacteria. There-
fore, it is not surprising that SP demonstrated bacteriostatic,
but not bactericidal, activity. It is noteworthy that SP and
most of the antibacterial peptides analyzed in this study (Ta-
ble 1) are active in the low micromolar concentration range,
and that SP is only 11 amino acids long. However, SP was
toxic at higher concentrations than the antibacterial peptides
in Table 1. We are currently working to use APAP to design
more e¡ective antibacterial peptides with higher TI values.
In conclusion, we have described a computational ap-
proach, APAP, to identify PAPs. These peptides display se-
lectivity towards bacteria and mitochondria, with little toxic
e¡ect on eukaryotic cells when applied extracellularly, thus
providing the basis for a new generation of drugs that can
be present in the body without toxic e¡ect unless they are
taken in by targeted cells as we have shown previously [1].
From a public database, the approach detected mostly anti-
bacterial peptides and neuropeptides suggesting that these
neuropeptides may be the ¢rst reported with antibacterial ac-
tivity. In agreement with this idea, we reported that SP is a
PAP with a TIs 100. We speculate that these activities have
been present in SP during the course of evolution of the
tachykinins, which would support the possibility of a biolog-
ical signi¢cance for these ¢ndings. APAP provides a method
to detect and ultimately improve pro-apoptotic peptides for
chemotherapy.
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